USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$127.56M
Market Cap
-
P/E Ratio
-1.3
EPS
$4.98
52 Week High
$1.35
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$359K |
| Total Revenue | $0 |
| Cost Of Revenue | $359K |
| Costof Goods And Services Sold | $359K |
| Operating Income | -$71M |
| Selling General And Administrative | $19M |
| Research And Development | $52M |
| Operating Expenses | $70M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $359K |
| Income Before Tax | -$36M |
| Income Tax Expense | $431K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$36M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$36M |
| Ebitda | -$35M |
| Net Income | -$36M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$359K |
| Total Revenue | $0 |
| Cost Of Revenue | $359K |
| Costof Goods And Services Sold | $359K |
| Operating Income | -$71M |
| Selling General And Administrative | $19M |
| Research And Development | $52M |
| Operating Expenses | $70M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $359K |
| Income Before Tax | -$36M |
| Income Tax Expense | $431K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$36M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$36M |
| Ebitda | -$35M |
| Net Income | -$36M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, focused on developing innovative therapies for patients suffering from autoimmune diseases and amyotrophic lateral sclerosis (ALS), with a particular emphasis on those requiring organ or cell transplantation. The company is advancing its proprietary drug candidates through rigorous clinical trials aimed at addressing substantial unmet medical needs within these patient demographics. With a strong pipeline and a strategic commitment to improving transplant outcomes, Eledon is well-positioned to make a significant contribution to the biopharmaceutical sector and improve the lives of patients facing these challenging health conditions.